Le Lézard
Classified in: Health
Subject: PDT

Bluegrass Vascular Announces Decision by Medicare to Assign a New Technology Ambulatory Payment Classification (APC) for the Surfacer® System Procedure

SAN ANTONIO, Sept. 20, 2021 /PRNewswire/ -- Bluegrass Vascular Technologies (Bluegrass Vascular), a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today that the Centers for Medicare & Medicaid Services (CMS) has finalized a new Healthcare Common Procedure Coding System (HCPCS) code and New Technology Ambulatory Payment Classification (APC) assignment for use of the Surfacer® Inside-Out® Access Catheter System (Surfacer System) procedure. The new code is C9780, Insertion of central venous catheter through central venous occlusion via inferior and superior approaches (e.g., inside-out technique), including imaging guidance. It is assigned to New Technology APC 1534, with a national average payment rate of $8,250.50. As a result of this decision, hospitals and ambulatory surgery centers (ASCs) will be able to utilize HCPCS code C9780 to report the Inside-Out procedure when performed with the Surfacer System beginning on October 1, 2021.

The Surfacer System employs a novel Inside-Out approach and is the first FDA cleared medical device to facilitate upper body central venous access in patients with venous obstructions or other conditions that preclude access by conventional methods.

"The CMS decision to assign a New Technology APC for the Surfacer System is a major milestone and will ensure that our innovative technology will be reimbursed for Medicare beneficiaries. This is a significant development, given the prevalence of thoracic central venous obstruction in patients dialyzing via a central venous catheter," stated Gabriele Niederauer, Ph.D., CEO and President of Bluegrass Vascular. "This decision is a testament to the positive clinical evidence and cost data that support the use of the Surfacer System as a critical, lifesaving technology."

Thoracic central venous obstruction occurs in roughly 40% of patients where hemodialysis is performed via a central venous catheter.1 While permanent arteriovenous fistulas are the preferred form of vascular access for hemodialysis patients, central venous catheters continue to serve as an important bridge to securing long-term access for life-saving hemodialysis treatment. The current approach for most patients with central venous obstructions is to use an alternative vein, which reduces the ability to place and mature a functioning fistula, resulting in increased catheter days and costs.

According to CMS, more than 62.4 million Americans are enrolled in the Medicare program.2 Approximately 80% of patients on hemodialysis are covered by Medicare fee-for-service as primary payer or by a Medicare Advantage managed care plan.3 Patients who live with kidney failure represent 1% of the total U.S. Medicare population yet account for 7% of the Medicare costs.4

The use of the Surfacer device also avoids left-side catheter placement, better enabling the maturation of permanent arteriovenous access options in the left arm and minimizing unnecessary access-related procedures and complications. The National Kidney Foundation's current Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Vascular Access recommend that the ideal access site for hemodialysis catheters is the right internal jugular vein. This preferred right-sided access path is supported by the Surfacer System's novel Don't Go Lefttm approach.

The Surfacer System received FDA De Novo clearance in the US in February and is CE marked in Europe. The device is available in North America, Europe and other territories.

About the Surfacer® Inside-Out® Access Catheter System

The Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient's venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. This proprietary Inside-Out approach allows for the placement and maturation of permanent arteriovenous access options that are associated with improved patient outcomes and reduced cost of care for both hospitals and hemodialysis providers.

About Bluegrass Vascular Technologies

Bluegrass Vascular Technologies is a medical technology company dedicated to developing and commercializing lifesaving devices and methods that address shortcomings in vascular access procedures. For more information, please visit www.bluegrassvascular.com.

1 Data on file at Bluegrass Vascular Technologies, Inc.
2 https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Fast-Facts
3 United States Renal Data System (USRDS) 2020 Annual Data Report
4 https://pharm.ucsf.edu/kidney/need/statistics

SOURCE Bluegrass Vascular Technologies

These press releases may also interest you

at 16:20
In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple...

at 16:20
Ionis Pharmaceuticals, Inc. partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense medicine being evaluated for people with superoxide dismutase 1...

16 oct 2021
Core One Labs Inc. , , (the "Company") a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, congratulates Seattle's city...

16 oct 2021
Neurocrine Biosciences, Inc.  today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 2021 Virtual Annual Meeting...

16 oct 2021
HLNY's highest recognition, the "Award of Distinction" will be presented to Arthur Gianelli, FACHE, Chief Transformation Officer of Mount Sinai Health System and President of Mount Sinai Morningside. This award recognizes a healthcare executive who...

16 oct 2021
Regulated Information ? Inside Information ? UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that they were unable to complete review of the Biologics License...

News published on 20 september 2021 at 08:02 and distributed by: